Windlas Biotech Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹238.50 crore, reflecting a quarter-on-quarter *(QoQ) increase of 2.32 per cent from ₹233.10 crore. This corresponds to a year-on-year *(YoY) growth of 17.66 per cent.
Operating Profit
Operating Profit stands at ₹25.29 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.78 per cent from ₹24.37 crore. This corresponds to a year-on-year *(YoY) decline of 1.02 per cent.
PBDT
PBDT stands at ₹28.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.81 per cent from ₹27.67 crore. This corresponds to a year-on-year *(YoY) decline of 3.43 per cent.
Profit Before Tax
Profit Before Tax stands at ₹20.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.00 per cent from ₹19.97 crore. This corresponds to a year-on-year *(YoY) decline of 3.17 per cent.
Net Profit
Net Profit stands at ₹15.99 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.60 per cent from ₹15.00 crore. This represents a 1.78 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Windlas Biotech Ltd Earnings
- YOY
- QOQ
Windlas Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Windlas Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Windlas Biotech Ltd Financial Reports
Windlas Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Windlas Biotech | 0.74% | -1.45% | -19.04% | 3.52% | 3.90% | -7.29% |
| Panacea Biotec | 2.56% | -0.82% | -13.78% | -23.36% | -12.10% | -26.56% |
| Syncom Formul. | -1.40% | -6.18% | -22.15% | 55.11% | 48.80% | 22.40% |
| Hester Bios | 3.11% | 4.44% | 4.04% | -9.94% | 35.20% | 38.86% |
| Titan Biotech | 6.85% | 4.05% | 11.07% | 3.56% | -8.51% | 97.73% |
| Venus Remedies | -3.63% | -7.42% | -22.12% | -17.17% | 42.85% | 205.18% |
| NGL Fine Chem | -0.08% | -1.23% | -8.80% | -19.26% | 15.60% | 81.03% |
Company Info
Company Information
Chairman & Independent Directo : Vivek Dhariwal
WTD & Executive Director : ASHOK KUMAR WINDLASS
Joint MD & Executive Director : MANOJ KUMAR WINDLASS
Executive Director & MD : HITESH WINDLASS
Independent Non Exe. Director : Gaurav Gulati
Non Executive Director : Prachi Jain Windlass
Executive Director : Pawan Kumar Sharma
Independent Non Exe. Director : Tarashree Singhal
Company Sec. & Compli. Officer : Ananta Narayan Panda